CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.34BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9530xvs all stocks
52-Week Change
12.46%vs all stocks
Market Capitalization
2.34BUSDvs all stocks (USD)
Enterprise Value
1.92BUSDvs all stocks (USD)
Forward P/E
-7.64xvs Biotechnology peers
Price to Book (MRQ)
5.74xvs Biotechnology peers
Enterprise to EBITDA
-4.63xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-46.76%vs Biotechnology peers
Return on Equity (TTM)
-91.75%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-415.22MUSDvs all stocks (USD)
Net Income (TTM)
-401.90MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-338.65MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-212.95MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-315.47MUSDvs all stocks (USD)
Pre-tax Income
-299.61MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.00KUSDFY2025 · Dec 31, 2025Net Income
-299.62MUSDFY2025 · Dec 31, 2025EBIT
-292.08MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-291.62MUSDFY2025 · Dec 31, 2025Research & Development
215.26MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
100.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
24.48MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.53MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-299.62MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-244.64MUSDFY2025 · Dec 31, 2025Free Cash Flow
-245.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
354.73MUSDFY2025 · Dec 31, 2025Interest Paid
6.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-299.62MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
468.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
37.93MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.11MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
13.91MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.43MUSDFY2025 · Dec 31, 2025Capital Expenditures
-630.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-310.45MUSDFY2025 · Dec 31, 2025Sale of Investments
506.16MUSDFY2025 · Dec 31, 2025Other Investing Activity
-800.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
194.29MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
23.34MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-21.92MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
301.92MUSDFY2025 · Dec 31, 2025Shares Outstanding
71.96MSharesUpdated Sep 28, 2026Float Shares
52.39MSharesUpdated Sep 28, 2026Shares Short
17.04MSharesUpdated Sep 28, 2026Short Ratio
7.29daysvs all stocks
Short % of Shares Outstanding
26.91%vs all stocks
% Held by Insiders
0.95%vs all stocks
% Held by Institutions
117.95%vs all stocks
Total Cash (MRQ)
499.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.93USDUpdated Sep 28, 2026Total Debt (MRQ)
76.91MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1886xvs Biotechnology peers
Current Ratio (MRQ)
10.92xvs Biotechnology peers
Book Value per Share (MRQ)
5.67USDUpdated Sep 28, 2026Total Assets
734.73MUSDvs all stocks (USD)
Total Current Assets
728.88MUSDFY2025 · Dec 31, 2025Total Liabilities
130.21MUSDFY2025 · Dec 31, 2025Total Non-current Assets
5.85MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
76.76MUSDFY2025 · Dec 31, 2025Total Current Liabilities
53.45MUSDFY2025 · Dec 31, 2025Cash
4.62MUSDFY2025 · Dec 31, 2025Cash Equivalents
350.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
354.73MUSDFY2025 · Dec 31, 2025Other Short-term Investments
359.86MUSDFY2025 · Dec 31, 2025Accounts Payable
21.90MUSDFY2025 · Dec 31, 2025Short-term Debt
549.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.37MUSDFY2025 · Dec 31, 2025Long-term Debt
76.76MUSDFY2025 · Dec 31, 2025Common Stock (Book)
71.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-760.87MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
604.52MUSDvs all stocks (USD)
52-Week Low
23.05USDUpdated Sep 28, 202652-Week High
56.05USDUpdated Sep 28, 202652-Week Change
12.46%vs all stocks
Beta
0.9530xvs all stocks
50-Day MA
33.74USDUpdated Sep 28, 2026200-Day MA
39.46USDUpdated Sep 28, 2026Avg 10-Day Volume
3.24MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.50MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-5.92USDUpdated Sep 28, 2026Other Income / Expense
-1.09MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.62
Altman Z-Score 9.13: safe zoneNotable
Altman Z-Score: 9.13
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,820,060.775
Levered free cash flow is -$212.95M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -212,947,376Global P5: -204,451,341.808
Market cap is $2.34B, above the global median of $1.2BNotable
Market cap (USD): 2,342,058,387Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Nurix Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
BrightGene Bio-Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk